Fundz

Akeso Biomedical, Inc. reported raising $574,000 in an initial SEC Form D filing, from an offering of $1 Million

PRIVATEFeb 12, 2021$573.9K of $1M raised

Amount Raised

$574,000

$574,000 sold, per SEC Form D (first sale Feb 12, 2021)

Round Type

Seed

BurlingtonOtherHealthcare

Quick answer

Akeso Biomedical, Inc. raised $574,000 in a Seed round, dated February 12, 2021. Akeso Biomedical, Inc. is based in Burlington, Massachusetts, United States.

How much did Akeso Biomedical, Inc. raise?
Akeso Biomedical, Inc. raised $574,000 in a Seed round on February 12, 2021.
What does Akeso Biomedical, Inc. do?
Akeso Biomedical, Inc. is an early stage company focused on developing new solutions for the treatment of bacterial infections, microbial biofilms, and chronic wounds.
Where is Akeso Biomedical, Inc. based and how big is it?
Akeso Biomedical, Inc. is based in Burlington, Massachusetts, United States.
Who are the decision-makers at Akeso Biomedical, Inc?
Fundz holds 1 contact at Akeso Biomedical, Inc., including the Executive Officer, Director. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Healthcare around the same time

Companies in the same sectors as Akeso Biomedical, Inc. that raised within 45 days of this round, from Fundz verified event records.

  • Pyx Health raised $12M on March 29, 2021.
  • Klowen Braces raised $6M on March 26, 2021.
  • Clearsense raised $30M (Funding Round) on March 26, 2021.
  • Pression raised $370K (Seed) on March 26, 2021.
  • Endolytix Technology raised $12M on March 26, 2021.
  • Azora Therapeutics, Inc. (DE) raised $291K on March 26, 2021.

Who to call at Akeso Biomedical, Inc., and when

A new round usually means Akeso Biomedical, Inc. is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Akeso Biomedical, Inc. raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Akeso Biomedical, Inc., from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Akeso Biomedical, Inc.. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Akeso Biomedical, Inc.

Location

2400 District Avenue, Suite 110

Burlington, Massachusetts, United States

About

Akeso Biomedical, Inc. is an early stage company focused on developing new solutions for the treatment of bacterial infections, microbial biofilms, and chronic wounds. The Company is developing products to treat these conditions using a new class of compounds, known as Fe3C, that have broad-spectrum activity against a wide range of bacteria, and a silk biomaterial technology exclusively licensed from Tufts University. Akeso’s lead Fe3C product is a feed additive designed to prevent food poisoning by Campylobacter, a bacteria that causes more cases of foodborne illness in the EU than Salmonella, E. coli and Listeria combined, with an estimated 280,000 cases in the UK and 1.3 million cases in the US each year. The economic cost of treating patients infected with Campylobacter in the UK is reported to be $1.5 billion, and over $5.6 billion in the US.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Akeso Biomedical, Inc. raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contactsSimon W., Executive Officer, DirectorSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Akeso Biomedical, Inc.'s next move

See what Strategic adds

Akeso Biomedical, Inc. raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.